<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TIH</journal-id>
<journal-id journal-id-type="hwp">sptih</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Ind Health</journal-id>
<journal-title>Toxicology and Industrial Health</journal-title>
<issn pub-type="ppub">0748-2337</issn>
<issn pub-type="epub">1477-0393</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0748233712436640</article-id>
<article-id pub-id-type="publisher-id">10.1177_0748233712436640</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>In vitro</italic> evaluation of the protective effects of 4-thujanol against mitomycin-C and cyclophosphamide-induced genotoxic damage in human peripheral lymphocytes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kocaman</surname>
<given-names>Ayşe Yavuz</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233712436640">1</xref>
<xref ref-type="corresp" rid="corresp1-0748233712436640"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>İstifli</surname>
<given-names>Erman Salih</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233712436640">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Büyükleyla</surname>
<given-names>Mehmet</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233712436640">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rencüzoğulları</surname>
<given-names>Eyyüp</given-names>
</name>
<xref ref-type="aff" rid="aff3-0748233712436640">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Topaktaş</surname>
<given-names>Mehmet</given-names>
</name>
<xref ref-type="aff" rid="aff4-0748233712436640">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0748233712436640"><label>1</label>Department of Biology, Mustafa Kemal University, Turkey</aff>
<aff id="aff2-0748233712436640"><label>2</label>Department of Biology, Basic and Applied Sciences Institute, Çukurova University, Turkey</aff>
<aff id="aff3-0748233712436640"><label>3</label>Department of Biology, Adıyaman University, Turkey</aff>
<aff id="aff4-0748233712436640"><label>4</label>Department of Biology, Çukurova University, Turkey</aff>
<author-notes>
<corresp id="corresp1-0748233712436640">Ayşe Yavuz Kocaman, Department of Biology, Mustafa Kemal University, 31000 Hatay, Turkey. Email: <email>aysekocaman@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>29</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>37</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>4-Thujanol (sabinene hydrate), a bicyclic monoterpene alcohol, is found in the essential oils of many aromatic and medicinal plants and is widely used as a fragrance and flavouring agent in many different products. The aim of this study was to evaluate the protective effects of 4-thujanol against the genotoxic effects induced by mitomycin C (MMC) and cyclophosphamide (CP) in human lymphocytes, using the chromosome aberrations, sister chromatid exchanges, and micronucleus tests, in the absence and in the presence of S9 mix, respectively. The cells were treated with 0.25 µg/mL MMC and 28 µg/mL CP as alone and cotreated with 13 + 0.25, 26 + 0.25, and 52 + 0.25 µg/mL 4-thujanol + MMC and with 13 + 28, 26 + 28, and 52 + 28 µg/mL 4-thujanol + CP as a mixture. The present study showed that 4-thujanol was unable to reduce the genetic damage induced by MMC, in the absence of S9 mix. On the other hand, probably the metabolites of 4-thujanol act as an antagonist and markedly antagonize CP-induced genotoxicity, in the presence of S9 mix. In general, 4-thujanol + MMC and 4-thujanol + CP decreased the mitotic index, proliferation index and nuclear division index to the same extent or more than those of individual exposure of MMC or CP. In conclusion, 4-thujanol significantly reduced (<italic>p</italic> &lt; 0.001) the genotoxic damage induced by CP but not MMC when compared with the respective positive control alone. We can suggest that 4-thujanol may improve the chemopreventive effects and may also reduce the harmful side effects of CP, which is widely used in chemotherapy against cancer, without reducing its antiproliferative activities.</p>
</abstract>
<kwd-group>
<kwd>4-thujanol</kwd>
<kwd>human peripheral lymphocytes</kwd>
<kwd>antagonistic effect</kwd>
<kwd>chromosome aberrations</kwd>
<kwd>sister chromatid exchanges</kwd>
<kwd>micronucleus</kwd>
<kwd>mitomycin C</kwd>
<kwd>cyclophosphamide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0748233712436640">
<title>Introduction</title>
<p>Monoterpenes are a class of terpenes that are biosynthetically derived from isoprene units with the molecular formula C<sub>10</sub>H<sub>16</sub>. They are non-nutritive dietary components and are found in the essential oils of many plants including fruits, vegetables, and herbs. A variety of monoterpenes and their derivatives have been found as antioxidant, antimicrobial, anti-inflammatory, and antitumor substances (<xref ref-type="bibr" rid="bibr14-0748233712436640">Candan et al., 2003</xref>; <xref ref-type="bibr" rid="bibr36-0748233712436640">Kordalı et al., 2005</xref>; <xref ref-type="bibr" rid="bibr43-0748233712436640">Mitić-Ćulafić et al., 2009</xref>; <xref ref-type="bibr" rid="bibr46-0748233712436640">Moteki et al., 2002</xref>; <xref ref-type="bibr" rid="bibr50-0748233712436640">Pattnaik et al., 1997</xref>; <xref ref-type="bibr" rid="bibr57-0748233712436640">Santos et al., 2004</xref>; <xref ref-type="bibr" rid="bibr62-0748233712436640">Tepe et al., 2004</xref>). Some of these substances have also been shown to possess cancer chemopreventive and chemotherapeutic properties (<xref ref-type="bibr" rid="bibr20-0748233712436640">Crowell, 1999</xref>; <xref ref-type="bibr" rid="bibr27-0748233712436640">Gould, 1997</xref>; <xref ref-type="bibr" rid="bibr58-0748233712436640">Slamenova et al., 2011</xref>).</p>
<p>4-Thujanol (sabinene hydrate), a natural bicyclic monoterpene alcohol, is found in the essential oils of many medicinal and aromatic plants (<xref ref-type="bibr" rid="bibr2-0748233712436640">Al-Kalaldeh et al., 2010</xref>; <xref ref-type="bibr" rid="bibr37-0748233712436640">Köse et al., 2010</xref>; <xref ref-type="bibr" rid="bibr56-0748233712436640">Sangun et al., 2007</xref>). Because of its woody, minty, and spicy odour, 4-thujanol has been commonly used as a fragrance agent in many different products including fine fragrances, shampoos, soaps, household cleaners, and detergents (<xref ref-type="bibr" rid="bibr10-0748233712436640">Bhatia et al., 2008</xref>) and also used as a flavouring agent in a variety of food products and beverages (<xref ref-type="bibr" rid="bibr63-0748233712436640">VCF, 2010</xref>).</p>
<p>Although monoterpenes are commonly regarded as safe substances, some of them have been found to be genotoxic, mutagenic, and cytotoxic in various test systems (<xref ref-type="bibr" rid="bibr7-0748233712436640">Azirak and Rencuzogullari, 2008</xref>; <xref ref-type="bibr" rid="bibr13-0748233712436640">Buyukleyla and Rencuzogullari, 2009</xref>; <xref ref-type="bibr" rid="bibr26-0748233712436640">Gomes-Carneiro et al., 1998</xref>; <xref ref-type="bibr" rid="bibr49-0748233712436640">Nishida et al., 2005</xref>). We recently found that 4-thujanol had a genotoxic effect at 13, 26, and 52 µg/mL concentrations but had no cytotoxic potential in human peripheral blood lymphocytes (PBLs) <italic>in vitro</italic> (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>). Although, 4-thujanol induced DNA damage at these concentrations (13, 26, and 52 µg/mL) (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>), in the present study, we aimed to determine if 4-thujanol could possess antagonistic (and, hence, chemopreventive) effects against mitomycin C (MMC) and cyclophosphamide (CP) induced genetic damage in human PBLs.</p>
<p>MMC and CP are widely used anticancer drugs. However, it is known that many anticancer drugs have been found to be mutagenic, teratogenic, and carcinogenic in <italic>in vitro</italic> and <italic>in vivo</italic> test systems, and secondary malignancies are known to be associated with several therapeutic treatments (<xref ref-type="bibr" rid="bibr31-0748233712436640">IARC, 1987</xref>; <xref ref-type="bibr" rid="bibr59-0748233712436640">Sorsa et al., 1985</xref>).</p>
<p>It is known that genotoxicity assessment of the particular compounds is the evaluation of their ability to induce any change in the genetic material such as gene mutations, chromosomal rearrangements or deletions, and loss or gain of a whole chromosome. Chromosome aberrations (CAs), sister chromatid exchanges (SCEs), and micronucleus (MN) formation in PBLs are among the most widely used and well-established assays for the detection of early biological effects induced by DNA damaging agents (<xref ref-type="bibr" rid="bibr12-0748233712436640">Bonassi et al., 2005</xref>; <xref ref-type="bibr" rid="bibr15-0748233712436640">Carrano and Natarajan, 1988</xref>). Any reduction in the frequency of CAs, SCEs, and MN gives an indication of the protective effect of a particular substance (<xref ref-type="bibr" rid="bibr1-0748233712436640">Albertini et al., 2000</xref>).</p>
<p>Numerous studies were performed to assess the protective effects of plant extracts and/or their isolated bioactive components against genotoxicity induced by mutagenic agents using the CA, SCE, and MN tests in human PBLs (<xref ref-type="bibr" rid="bibr3-0748233712436640">Ananthi et al., 2010</xref>; <xref ref-type="bibr" rid="bibr18-0748233712436640">Celikler et al., 2008</xref>, <xref ref-type="bibr" rid="bibr17-0748233712436640">2009</xref>; <xref ref-type="bibr" rid="bibr21-0748233712436640">Di Sotto et al., 2010</xref>; <xref ref-type="bibr" rid="bibr32-0748233712436640">Kayraldiz et al., 2010</xref>; <xref ref-type="bibr" rid="bibr53-0748233712436640">Rencuzogullari et al., 2006</xref>; <xref ref-type="bibr" rid="bibr60-0748233712436640">Sowjanya et al., 2009</xref>). However, to our knowledge, no studies are available in the scientific literature on the combined effects of 4-thujanol with any known mutagenic substance for determining the protective effects of this monoterpene.</p>
<p>Therefore, the aim of the present study was to evaluate the possible protective effects of 4-thujanol against the genetic damage induced by MMC and CP, known as alkylating mutagenic agents, in human PBLs using the CAs, SCEs, and MN tests in the absence and presence of the metabolic activator (S9 mix), respectively.</p>
</sec>
<sec id="section2-0748233712436640" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0748233712436640">
<title>Test samples and chemicals</title>
<p>The project was approved by the Institutional Ethics Committee of Mustafa Kemal University, Antakya. This study was carried out using human peripheral blood samples from two healthy, nonsmoking volunteer donors (one male and one female) aged 21 years. Both the donors had no known excess exposure to genotoxicants.</p>
<p>4-Thujanol was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). The chemical structure of 4-thujanol is shown in <xref ref-type="fig" rid="fig1-0748233712436640">Figure 1</xref> and its properties are shown as follows:</p>
<fig id="fig1-0748233712436640" position="float">
<label>Figure 1.</label>
<caption>
<p>The chemical structure of 4-thujanol.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436640-fig1.tif"/>
</fig>
<p>
<list list-type="simple">
<list-item>
<p>
<italic>Synonyms</italic>: Bicyclo[3.1.0]hexan-2-ol, 2-methyl-5-(1-methylethyl)-; 2-methyl-5-(1-methylethyl)bicyclo(3.1.0)hexan-2-ol; sabinene hydrate; 4-thujanol</p>
</list-item>
<list-item>
<p>
<italic>CAS Registry Number</italic>: 546-79-2</p>
</list-item>
<list-item>
<p>
<italic>EINECS Number</italic>: 208-911-7</p>
</list-item>
<list-item>
<p>
<italic>Chemical Formula</italic>: C<sub>10</sub>H<sub>18</sub>O</p>
</list-item>
<list-item>
<p>
<italic>Molecular weight</italic>: 154.25</p>
</list-item>
<list-item>
<p>
<italic>Purity</italic>: ≥97.0%</p>
</list-item>
</list>
</p>
<p>4-Thujanol was dissolved in 50% ethanol supplied by Merck (Darmstadt, Germany), which was also tested as solvent control. 5-Bromodeoxyuridine (B-5002), colchicine (C-9754), and cytochalasin B (C-6762) were purchased from Sigma. In the cultures without metabolic activation, the positive control was MMC (M-05030; Sigma) at 0.25 µg/mL for treatments. For cultures with metabolic activation, CP monohydrate (28 µg/mL, C-0768; Sigma) was used as a positive control at 28 µg/mL for <italic>in vitro</italic> tests. Giemsa stain and all other chemicals were purchased from Merck. All test solutions were freshly prepared prior to each experiment.</p>
</sec>
<sec id="section4-0748233712436640">
<title>Concentration selection</title>
<p>In the previous study from this laboratory, we investigated the <italic>in vitro</italic> genotoxic effects of 4-thujanol at the concentrations of 13, 26, and 52 µg/mL in human peripheral lymphocytes (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>). In the present work, for determining the combined effects of the 4-thujanol with mutagenic agents, MMC and CP as relative to the induction of genetic damage by MMC (0.25 µg/mL) and CP (28 µg/mL) alone, concentrations of 13, 26, and 52 µg/mL 4-thujanol were chosen.</p>
</sec>
<sec id="section5-0748233712436640">
<title>
<italic>
<italic>In vitro</italic>
</italic> assay (without S9 mix)</title>
<p>The CA and SCE tests were performed using the methods developed by <xref ref-type="bibr" rid="bibr24-0748233712436640">Evans (1984</xref>) and <xref ref-type="bibr" rid="bibr52-0748233712436640">Perry and Thompson (1984</xref>), with minor modification. This study was conducted according to International Programme on Chemical Safety (IPCS) guidelines (<xref ref-type="bibr" rid="bibr1-0748233712436640">Albertini et al., 2000</xref>). Lymphocyte cultures were setup by adding 0.2 mL of whole blood from two healthy donors to 2.5 mL of chromosome medium PB Max (cat. no. 12552-013; Gibco, Carlsbad, CA, USA) supplemented with 10 µg/mL of bromodeoxyuridine. Cultures were incubated at 37°C for 72 h.</p>
<p>Serial dilutions of 4-thujanol was made in ethanol under sterile conditions; thus, ethanol (50% ethanol, 4 µL/mL) was used as a solvent control. A control (i.e. untreated control) and a positive control (0.25 µg/mL MMC) were also established for each experiment. Treatments were conducted at 24 h (4-thujanol and MMC were added 48 h after initiating the culture) and 48 h (4-thujanol and MMC were added 24 h after initiating the culture). To arrest the cells in metaphase, the cells were exposed to 0.06 μg/mL colchicine 2 h before harvesting. The cells were centrifuged at 2000 r/min for 5 min. The supernatant was removed and the cells treated with a hypotonic solution (0.4% KCl) for 15 min at 37°C. The supernatant was removed after centrifugation at 1200 r/min for 15 min and then fixed three times in a cold solution consisting of methanol:glacial acetic acid (3:1 v/v) at room temperature (22 ± 1°C). Finally, the centrifuged cells were dropped onto clean slides. The staining of the air-dried slides was performed following the standard methods using 5% Giemsa stain for the CA analysis (i.e. with 5% Giemsa stain in Sorensen’s buffer, pH 6.8, 15 min) and the modified fluorescence plus Giemsa (FPG) method for the SCE analysis (<xref ref-type="bibr" rid="bibr61-0748233712436640">Speit and Haupter, 1985</xref>). For FPG staining, 1-day-old slides were covered with Sorensen’s buffer (pH 6.8). Then, the slides were irradiated with 30 W, 254 nm UV lamp at 15 cm distance for 30 min. After irradiation, the slides were incubated in 1× standard saline citrate at 58–60°C for 60 min and then stained for 20 min with 5% Giemsa stain prepared with Sorensen’s buffer.</p>
<p>For the MN test, 0.2 mL of fresh blood was used to establish the cultures and the cultures were incubated at 37°C for 68 h. The cells were cotreated with 13 + 0.25, 26 + 0.25, and 52 + 0.25 μg/mL concentrations of 4-thujanol + MMC for 24- and 48-h (4-thujanol + MMC was added 44 and 20 h after initiating the culture, respectively) treatment periods. Cytochalasin B (final concentration of 6 μg/mL) was added after 44 h of incubation in order to block cytokinesis and to obtain binucleated cells. After an additional 24 h of incubation at 37°C, cells were harvested by centrifugation and slides were prepared for MN test (<xref ref-type="bibr" rid="bibr25-0748233712436640">Fenech, 2000</xref>; <xref ref-type="bibr" rid="bibr34-0748233712436640">Kirsch-Volders et al., 2003</xref>). Finally, slides were stained with 5% Giemsa stain in Sorensen’s buffer (pH 6.8) for 13 min.</p>
</sec>
<sec id="section6-0748233712436640">
<title>
<italic>
<italic>In vitro</italic>
</italic> assay (with S9 mix)</title>
<p>In general, the same procedure for the CA, SCE, and MN assays described earlier were used to assess the indirect antagonistic effect of 4-thujanol against MMC- and CP-induced genetic damage, with minor modifications depending on the methodology of the metabolic activation. The lymphocytes were cotreated with 13 + 28, 26 + 28, and 52 + 28 μg/mL concentrations of 4-thujanol + CP and 0.5 mL S9 mix for 3 h. 4-Thujanol + CP and S9 mix were added 48 h after initiating the culture. For every culture of lymphocytes with the tested compound, a control, a solvent control (50% ethanol, 4 µL/mL), and a positive control (CP, 28 μg/mL) were also performed. In the presence of S9 mix, CP was used as a positive control because CP required a metabolic activator for the presence of its mutagenic effect. The test chemicals (4-thujanol and CP) and S9 mix were removed from the culture by centrifuging for 4 min at 2500 r/min. The pellet of lymphocytes was washed twice with 2.5 mL RPMI medium (Biochrom AG, Berlin, Germany, F 1215) and resuspended in fresh complete medium (chromosome medium PB Max). The cultures were incubated for a total of 72 h at 37°C for the CA and the SCE assays and 68 h at 37°C for the MN assay.</p>
<sec id="section7-0748233712436640">
<title>Preparation of S9</title>
<p>The albino male rats (<italic>Rattus norvegicus</italic> var. albinos) weighing 200 g were pretreated with 80 mg/kg concentration of 3-methylcholanthrene (dissolved in sunflower oil) for 5 days. For the preparation of S9 fraction and S9 mix, the method described by <xref ref-type="bibr" rid="bibr42-0748233712436640">Maron and Ames (1983</xref>) was employed.</p>
</sec>
</sec>
<sec id="section8-0748233712436640">
<title>Microscopic evaluation</title>
<sec id="section9-0748233712436640">
<title>Chromosomal aberrations</title>
<p>For each donor, a total of 100 well-spread metaphases were investigated (a total of 200 metaphase spreads for two donors) in order to score the CAs at each concentration and treatment period that showed structural CAs. The CA was classified according to International System for Human Cytogenetic Nomenclature (<xref ref-type="bibr" rid="bibr51-0748233712436640">Paz-y-Miño et al., 2002</xref>) and evaluated as chromatid-type (breaks, sister unions, and exchanges) and chromosome-type (breaks, dicentrics, rings, and fragments) aberrations. Gaps were not considered as CA according to <xref ref-type="bibr" rid="bibr39-0748233712436640">Mace et al. (1978</xref>). Percentage of cells with structural CAs has been calculated following the scoring of CAs.</p>
</sec>
<sec id="section10-0748233712436640">
<title>Sister chromatid exchanges</title>
<p>The scoring of SCE was performed according to the IPCS guidelines (<xref ref-type="bibr" rid="bibr1-0748233712436640">Albertini et al., 2000</xref>). The slides were coded before scoring and 25 well-differentiated second-division metaphase cells were analyzed per donor (a total of 50 second-division metaphases for each concentration) and the frequency of SCE per cell was recorded.</p>
</sec>
<sec id="section11-0748233712436640">
<title>Micronuclei</title>
<p>The scoring criteria used for the binuclear cell and MN evaluation were adopted by the HUman MicroNucleus Project (<xref ref-type="bibr" rid="bibr11-0748233712436640">Bonassi et al., 2001</xref>). To determine MN formation, 2000 binucleated cells were analyzed for each donor (4000 binucleated cells were scored per concentration). We evaluated the binucleate micronucleated lymphocytes containing one or more MN per 2000 binucleated cells.</p>
</sec>
<sec id="section12-0748233712436640">
<title>Reduction (%)</title>
<p>The percentage reduction in the number of cells treated with 4-thujanol plus MMC and CP (an indication of a protective effect) was calculated according to <xref ref-type="bibr" rid="bibr40-0748233712436640">Manoharan and Banerjee (1985</xref>) and <xref ref-type="bibr" rid="bibr67-0748233712436640">Waters et al. (1990</xref>) by the following formula<disp-formula id="disp-formula1-0748233712436640">
<mml:math id="mml-disp1-0748233712436640">
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">R</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">d</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mi mathvariant="normal">%</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mo stretchy="false">=</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mtext>number of cells with X in A</mml:mtext>
<mml:mo stretchy="false">−</mml:mo>
<mml:mtext>number of cells with X in B </mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>number of cells with X in A</mml:mtext>
<mml:mtext> </mml:mtext>
<mml:mo stretchy="false">−</mml:mo>
<mml:mtext>number of cells with X in C</mml:mtext>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mn mathvariant="normal">100</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula1-0748233712436640" xlink:href="10.1177_0748233712436640-eq1.tif"/>
</disp-formula> According to the formula, X represents the structural CA, SCE, or MN, and A is the group of cells treated with the respective positive control (MMC or CP), B is the group of cells treated with the solvent control, and C is the group of cells treated with 4-thujanol plus positive control.</p>
</sec>
<sec id="section19-0748233712436640">
<title>MI, PI and NDI</title>
<p>The mitotic index was calculated from the number of metaphases in 3000 cells analyzed per culture for each donor (6000 cells per concentration) in the CA assay. Furthermore, in order to determine the mixture effects of 4-thujanol plus positive control relative to positive control alone, the relative MI (RMI) was calculated as follows<disp-formula id="disp-formula2-0748233712436640">
<mml:math id="mml-disp2-0748233712436640">
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mtext>RMI (%) = MI value of test substance</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mtext mathvariant="normal">+</mml:mtext>
</mml:mrow>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">v</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mrow>
<mml:mo>/</mml:mo>
</mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mi mathvariant="normal">I</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">v</mml:mi>
<mml:mi mathvariant="normal">a</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
<mml:mi mathvariant="normal">u</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">f</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">p</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">s</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">i</mml:mi>
<mml:mi mathvariant="normal">v</mml:mi>
<mml:mi mathvariant="normal">e</mml:mi>
<mml:mtext mathvariant="normal"> </mml:mtext>
<mml:mi mathvariant="normal">c</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">n</mml:mi>
<mml:mi mathvariant="normal">t</mml:mi>
<mml:mi mathvariant="normal">r</mml:mi>
<mml:mi mathvariant="normal">o</mml:mi>
<mml:mi mathvariant="normal">l</mml:mi>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mn mathvariant="normal">100</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula2-0748233712436640" xlink:href="10.1177_0748233712436640-eq2.tif"/>
</disp-formula>
</p>
<p>In the SCE assay, a total of 200 cells (100 cells from each donor) were scored for the proliferation index. PI was calculated according to formula as follows<disp-formula id="disp-formula3-0748233712436640">
<mml:math id="mml-disp3-0748233712436640">
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">P</mml:mi>
<mml:mi mathvariant="normal">I</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">[</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">1</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mn mathvariant="normal">1</mml:mn>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">2</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
</mml:mrow>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>3</mml:mn>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
</mml:mrow>
<mml:mn>3</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mo mathvariant="normal" stretchy="false">]</mml:mo>
<mml:mrow>
<mml:mo>/</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mi>N</mml:mi>
</mml:math>
<graphic alternate-form-of="disp-formula3-0748233712436640" xlink:href="10.1177_0748233712436640-eq3.tif"/>
</disp-formula> where M1 (identifiable by uniform staining of both the sister chromatids), M2 (identifiable by differential staining of the sister chromatids), and M3 (identifiable by nonuniform pattern of staining) are the metaphases corresponding to first, second, and third divisions, and <italic>N</italic> is the total number of metaphases scored (<xref ref-type="bibr" rid="bibr38-0748233712436640">Lamberti et al., 1983</xref>). Relative PI (RPI) was calculated as<disp-formula id="disp-formula4-0748233712436640">
<mml:math id="mml-disp4-0748233712436640">
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mtext>RPI (%) = PI value of test substance</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mtext mathvariant="normal">+ positive control/PI value of positive control</mml:mtext>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mn mathvariant="normal">100</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula4-0748233712436640" xlink:href="10.1177_0748233712436640-eq4.tif"/>
</disp-formula>
</p>
<p>Moreover, in the MN assay, cytostaticity was calculated using the nuclear division index (NDI). To this aim, 1000 lymphocytes per donor were scored. 1000 cells with well-preserved cytoplasm, containing one to four nuclei were determined. NDI was calculated using the following formula<disp-formula id="disp-formula5-0748233712436640">
<mml:math id="mml-disp5-0748233712436640">
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">N</mml:mi>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">I</mml:mi>
<mml:mo mathvariant="normal" stretchy="false">=</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">[</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">1</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mn mathvariant="normal">1</mml:mn>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">2</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mn mathvariant="normal">2</mml:mn>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">3</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mn mathvariant="normal">3</mml:mn>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">+</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">(</mml:mo>
<mml:mn mathvariant="normal">4</mml:mn>
</mml:mrow>
</mml:mrow>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">M</mml:mi>
<mml:mn mathvariant="normal">4</mml:mn>
<mml:mo mathvariant="normal" stretchy="false">)</mml:mo>
<mml:mo mathvariant="normal" stretchy="false">]</mml:mo>
<mml:mrow>
<mml:mo>/</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mi>N</mml:mi>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0748233712436640" xlink:href="10.1177_0748233712436640-eq5.tif"/>
</disp-formula> where M1–M4 represent the number of cells with one to four nuclei and <italic>N</italic> is the total number of viable cells scored (<xref ref-type="bibr" rid="bibr23-0748233712436640">Eastmond and Tucker, 1989</xref>; <xref ref-type="bibr" rid="bibr25-0748233712436640">Fenech, 2000</xref>). Relative NDI (RNDI) was calculated using the following formula<disp-formula id="disp-formula6-0748233712436640">
<mml:math id="mml-disp6-0748233712436640">
<mml:mtable columnalign="right left" columnspacing="thickmathspace" displaystyle="true" rowspacing=".5em">
<mml:mtr>
<mml:mtd>
<mml:mtext>RNDI (%) = NDI value of test substance</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>+ positive control/NDI value of positive control</mml:mtext>
<mml:mo stretchy="false">×</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mn mathvariant="normal">100</mml:mn>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula6-0748233712436640" xlink:href="10.1177_0748233712436640-eq6.tif"/>
</disp-formula>
</p>
</sec>
</sec>
<sec id="section13-0748233712436640">
<title>Statistical analysis</title>
<p>The SPSS for Windows 16.0 computer program was used for statistical analysis. Statistical comparison of the results from controls, MMC, and CP groups was carried out by one-way analysis of variance test, and post hoc analysis of group differences was performed by the least significant difference test. Results are expressed as mean ± standard error. Concentration–response relationships were determined from the correlation and regression coefficients for the percentage of cells with structural CA, the mean SCE, the percentage of MN (MN %), as well as for the MI, PI, and NDI.</p>
</sec>
</sec>
<sec id="section14-0748233712436640">
<title>Results</title>
<p>The results of this study for each parameter values (CAs, SCEs, MN, MI, PI, and NDI) are presented in the tables. The effects of the combination of 4-thujanol and positive control (MMC or CP) on the CAs are summarized in <xref ref-type="table" rid="table1-0748233712436640">Tables 1</xref> and <xref ref-type="table" rid="table2-0748233712436640">2</xref>. 4-Thujanol + MMC and 4-thujanol + CP increased the structural CAs significantly for all concentrations and treatment periods in the absence and presence of S9 mix when compared with both the control and the solvent control (<italic>p</italic> &lt; 0.001). The MMC and CP at the concentrations of 0.25 and 28 µg/mL, respectively, significantly increased the percentage of cells with structural CAs compared with both the control and solvent control (<italic>p</italic> &lt; 0.001). The treatment of 4-thujanol + MMC as a mixture did not make a statistically significant change in the percentage of structural CAs, when compared with the MMC alone, in human PBLs. However, the mixtures of 4-thujanol + CP significantly decreased the CAs at all the concentrations when compared with CP (<italic>p</italic> &lt; 0.001). Furthermore, as seen in <xref ref-type="table" rid="table2-0748233712436640">Table 2</xref>, in the presence of S9 mix, the reduction in percentage of structural CAs was found to be 48.8, 56.2, and 43.7% in cotreatment of 4-thujanol + CP at 13 + 28, 26 + 28, and 52 + 28 µg/mL concentrations, respectively, when compared with that of CP alone.</p>
<table-wrap id="table1-0748233712436640" position="float">
<label>Table 1.</label>
<caption>
<p>Effect of 4-thujanol + MMC on the SCAs in human peripheral lymphocytes for 24- and 48-h treatment periods.</p>
</caption>
<graphic alternate-form-of="table1-0748233712436640" xlink:href="10.1177_0748233712436640-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th colspan="2">SCAs</th>
<th rowspan="2">Percentage of cells with SCAs ± SE</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
<th>Chromatid type</th>
<th>Chromosome type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td align="center">–</td>
<td align="center">–</td>
<td>6</td>
<td>1</td>
<td>3.50 ± 0.50</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>24</td>
<td>4 μL</td>
<td>9</td>
<td align="center">–</td>
<td>4.50 ± 0.50</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>24</td>
<td>0.25</td>
<td>82</td>
<td>29</td>
<td>36.00 ± 2.00<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>24</td>
<td>13 + 0.25</td>
<td>76</td>
<td>13</td>
<td>34.50 ± 1.50<sup>a3b3</sup>
</td>
<td>4.76</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>93</td>
<td>24</td>
<td>40.50 ± 2.50<sup>a3b3</sup>
</td>
<td>−14.28</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>139</td>
<td>36</td>
<td>52.50 ± 1.50<sup>a3b3c3</sup>
</td>
<td>−52.38</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>48</td>
<td>4 μL</td>
<td>9</td>
<td align="center">–</td>
<td>4.50 ± 0.50</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>48</td>
<td>0.25</td>
<td>381</td>
<td>83</td>
<td>84.00 ± 2.00<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>48</td>
<td>13 + 0.25</td>
<td>530</td>
<td>121</td>
<td>85.00 ± 3.00<sup>a3b3</sup>
</td>
<td>−1.25</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>522</td>
<td>72</td>
<td>85.50 ± 0.50<sup>a3b3</sup>
</td>
<td>−1.88</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>774</td>
<td>20</td>
<td>86.50 ± 2.50<sup>a3b3</sup>
</td>
<td>−3.14</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0748233712436640">
<p>SCA: structural chromosome aberrations; SC: solvent control; PC: positive control; MMC: mitomycin C; SE: standard error.</p>
</fn>
<fn id="table-fn2-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn3-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn4-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of MMC.</p>
</fn>
<fn id="table-fn6-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p </italic>&lt; 0.05.</p>
</fn>
<fn id="table-fn7-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p</italic> &lt; 0.01.</p>
</fn>
<fn id="table-fn8-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p </italic>&lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0748233712436640" position="float">
<label>Table 2.</label>
<caption>
<p>Effect of 4-thujanol + CP on the SCAs in human peripheral lymphocytes in the presence of S9 mix.</p>
</caption>
<graphic alternate-form-of="table2-0748233712436640" xlink:href="10.1177_0748233712436640-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th colspan="2">SCAs</th>
<th rowspan="2">Percentage of cells with SCAs ± SE</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
<th>Chromatid type</th>
<th>Chromosome type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>7</td>
<td>–</td>
<td>3.50 ± 0.50</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>3</td>
<td>4 μL</td>
<td>9</td>
<td>2</td>
<td>5.50 ± 0.50</td>
<td>
</td>
</tr>
<tr>
<td>PC (CP)</td>
<td>3</td>
<td>28</td>
<td>40</td>
<td>9</td>
<td>21.50 ± 0.50<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + CP</td>
<td>3</td>
<td>13 + 28</td>
<td>24</td>
<td>6</td>
<td>14.00 ± 1.00<sup>a3b3c3</sup>
</td>
<td>48.87</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 28</td>
<td>26</td>
<td>2</td>
<td>12.50 ± 0.50<sup>a3b3c3</sup>
</td>
<td>56.25</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 28</td>
<td>26</td>
<td>4</td>
<td>14.50 ± 0.50<sup>a3b3c3</sup>
</td>
<td>43.75</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0748233712436640">
<p>SCA: structural chromosome aberrations; SE: standard error; SC: solvent control; PC: positive control; CP: cyclophosphamide.</p>
</fn>
<fn id="table-fn10-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn11-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn12-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of CP.</p>
</fn>
<fn id="table-fn14-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p </italic>&lt; 0.05.</p>
</fn>
<fn id="table-fn15-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p </italic>&lt; 0.01.</p>
</fn>
<fn id="table-fn16-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p </italic>&lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The observed frequencies of SCE in the absence and in the presence of S9 mix in the PBLs are summarized in <xref ref-type="table" rid="table3-0748233712436640">Tables 3</xref> and <xref ref-type="table" rid="table4-0748233712436640">4</xref>, respectively. 4-Thujanol + MMC has induced SCE frequency significantly at all concentrations (13 + 0.25, 26 + 0.25, and 52 + 0.25 µg/mL) for 24-h and at 13 + 0.25 µg/mL concentration for 48-h treatment periods when compared with both the control and the solvent control, in the absence of S9 mix (<italic>p</italic> &lt; 0.001). However, due to cytostatic/antiproliferative effects of the combination of 4-thujanol + MMC at two higher concentrations for 48-h treatment period, the second metaphase cells could not be detected sufficiently. The positive control, MMC, significantly induced frequency of SCE \for both the treatment periods when compared with the control and the solvent control (<italic>p</italic> &lt; 0.001). 4-Thujanol + MMC induced the SCE frequency only as much as independent exposure of MMC. Although reductions in SCEs/cells were observed, cotreatment with 4-thujanol and MMC as compared to the MMC treatment alone (<xref ref-type="table" rid="table3-0748233712436640">Table 3</xref>), the inhibition was lower than 25%, so, according to <xref ref-type="bibr" rid="bibr48-0748233712436640">Negi et al. (2003</xref>), the effect cannot be considered as positive. In the presence of S9 mix, cotreatments with 4-thujanol + CP (4-thujanol and CP as a mixture) significantly increased the mean SCEs at all concentrations when compared with the control and solvent control in PBLs (<italic>p</italic> &lt; 0.001). CP significantly induced frequency of SCE when compared with control groups (<italic>p</italic> &lt; 0.001). But, there were reductions (16.4–54.8%) in SCE frequency when 4-thujanol was applied in combination with CP. These reductions are significant at 13 + 28 and 52 + 28 µg/mL concentrations of 4-thujanol + CP when compared with CP alone (<italic>p</italic> &lt; 0.001 and <italic>p</italic> &lt; 0.01, respectively; <xref ref-type="table" rid="table4-0748233712436640">Table 4</xref>).</p>
<table-wrap id="table3-0748233712436640" position="float">
<label>Table 3.</label>
<caption>
<p>The mean SCE values in cultured human lymphocytes treated with 4-thujanol + MMC for 24- and 48-h treatment periods.</p>
</caption>
<graphic alternate-form-of="table3-0748233712436640" xlink:href="10.1177_0748233712436640-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">Minimum–maximum SCE</th>
<th rowspan="2">SCE/cell ± SE</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>2–15</td>
<td>6.78 ± 0.10</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>24</td>
<td>4 μL</td>
<td>2–14</td>
<td>7.16 ± 0.44</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>24</td>
<td align="center">0.25</td>
<td>46–117</td>
<td>73.88 ± 4.61<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>24</td>
<td>13 + 0.25</td>
<td>44–111</td>
<td>65.66 ± 3.33<sup>a3b3</sup>
</td>
<td>12.32</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>30–130</td>
<td>72.42 ± 4.26<sup>a3b3</sup>
</td>
<td>2.18</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>40–98</td>
<td>70.15 ± 0.24<sup>a3b3</sup>
</td>
<td>5.59</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>48</td>
<td>4 μL</td>
<td>2–16</td>
<td>9.28 ± 0.76</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>48</td>
<td align="center">0.25</td>
<td>89–155</td>
<td>110.90 ± 9.4<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>48</td>
<td>13 + 0.25</td>
<td>78–120</td>
<td>101.15 ± 3.15<sup>a3b3</sup>
</td>
<td>9.59</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>
<sup>d</sup>
</td>
<td>
<sup>d</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>
<sup>d</sup>
</td>
<td>
<sup>d</sup>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0748233712436640">
<p>SCE: sister chromatid exchange; SE: standard error; SC: solvent control; PC: positive control; MMC: mitomycin C.</p>
</fn>
<fn id="table-fn18-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn19-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn20-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of MMC.</p>
</fn>
<fn id="table-fn22-0748233712436640">
<p>
<sup>d</sup>Insufficient second metaphase cells.</p>
</fn>
<fn id="table-fn23-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p </italic>&lt; 0.05.</p>
</fn>
<fn id="table-fn24-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p </italic>&lt; 0.01.</p>
</fn>
<fn id="table-fn25-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p </italic>&lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0748233712436640" position="float">
<label>Table 4.</label>
<caption>
<p>The mean SCE values in cultured human lymphocytes treated with 4-thujanol + CP in the presence of S9 mix.</p>
</caption>
<graphic alternate-form-of="table4-0748233712436640" xlink:href="10.1177_0748233712436640-table4.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">Minimum–maximum SCE</th>
<th rowspan="2">SCE/cell ± SE</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>1–13</td>
<td>7.91 ± 0.01</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>3</td>
<td>4 μL</td>
<td>3–13</td>
<td>6.98 ± 0.70</td>
<td>
</td>
</tr>
<tr>
<td>PC (CP)</td>
<td>3</td>
<td>28</td>
<td>8–32</td>
<td>17.22 ± 1.22<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + CP</td>
<td>3</td>
<td>13 + 28</td>
<td>6–23</td>
<td>11.60 ± 0.20<sup>a2b2c3</sup>
</td>
<td>54.88</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 28</td>
<td>8–30</td>
<td>15.54 ± 0.68<sup>a3b3</sup>
</td>
<td>16.40</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 28</td>
<td>6–26</td>
<td>13.56 ± 0.48<sup>a3b3c2</sup>
</td>
<td>35.74</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn26-0748233712436640">
<p>SCE: sister chromatid exchange; SE: standard error; SC: solvent control; PC: positive control; CP: cyclophosphamide.</p>
</fn>
<fn id="table-fn27-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn28-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn29-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of CP.</p>
</fn>
<fn id="table-fn31-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p</italic> &lt; 0.05.</p>
</fn>
<fn id="table-fn32-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p</italic> &lt; 0.01.</p>
</fn>
<fn id="table-fn33-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>4-Thujanol + MMC did not increase the percentage of the micronucleated binuclear cells (MNBN %) and the MN % for the 24-h treatment period when compared with the control and solvent control (<italic>p</italic> &gt; 0.05). However, 48-h treatment with 4-thujanol + MMC induced a significant increase in the MNBN % and MN % only at the lowest concentration (13 + 0.25 µg/mL) when compared with the control and solvent control (<italic>p</italic> &lt; 0.001). While at the two higher concentrations for 48-h treatment period, the binuclear cells could not be observed due to cytotoxic/cytostatic effects of the 4-thujanol + MMC (<xref ref-type="table" rid="table5-0748233712436640">Table 5</xref>). MNBN % and MN % were also not significantly increased when compared with both the control and solvent control in cells treated with all concentrations of 4-thujanol + CP in the presence of S9 mix (<xref ref-type="table" rid="table6-0748233712436640">Table 6</xref>). The combinations of 4-thujanol + MMC and 4-thujanol + CP did not show a statistically significant difference in MN formation when compared with those of the independent exposure of MMC and CP, respectively. However, according to the values of reduction (%), the lowest concentration of 4-thujanol + MMC (13 + 0.25 µg/mL) caused a reduction (29.5%) in MN formation when compared with that of MMC for the 24-h treatment period (<xref ref-type="table" rid="table5-0748233712436640">Table 5</xref>), and also except for the second concentrations of 4-thujanol + CP (13 + 28 and 52 + 28 µg/mL; reductions: 51.2 and 27.6%, respectively), it caused a reduction on the MN % when compared with independent exposure of CP in PBLs in the presence of S9 mix (<xref ref-type="table" rid="table6-0748233712436640">Table 6</xref>).</p>
<table-wrap id="table5-0748233712436640" position="float">
<label>Table 5.</label>
<caption>
<p>The percentage of MN and MNBN in cultured human lymphocytes treated with 4-thujanol + MMC for 24- and 48-h treatment periods.</p>
</caption>
<graphic alternate-form-of="table5-0748233712436640" xlink:href="10.1177_0748233712436640-table5.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">MNBN ± SE (%)</th>
<th rowspan="2">MN ± SE (%)</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>0.56 ± 0.16</td>
<td>0.56 ± 0.16</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>24</td>
<td>4 μL</td>
<td>0.37 ± 0.17</td>
<td>0.37 ± 0.17</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>24</td>
<td>0.25</td>
<td>1.08 ± 0.47</td>
<td>1.08 ± 0.47</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>24</td>
<td>13 + 0.25</td>
<td>0.87 ± 0.18</td>
<td>0.87 ± 0.18</td>
<td>29.57</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>1.38 ± 0.33</td>
<td>1.38 ± 0.33</td>
<td>−42.25</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>1.55 ± 0.50<sup>b1</sup>
</td>
<td>1.67 ± 0.62<sup>b1</sup>
</td>
<td>−83.09</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>48</td>
<td>4 μL</td>
<td>0.52 ± 0.12</td>
<td>0.55 ± 0.15</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>48</td>
<td>0.25</td>
<td>7.12 ± 0.87<sup>a3b3</sup>
</td>
<td>7.12 ± 0.87<sup>a3b3</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>48</td>
<td>13 + 0.25</td>
<td>12.89 ± 0.78<sup>a3b3c2</sup>
</td>
<td>14.85 ± 0.74<sup>a3b3c3</sup>
</td>
<td>−117.65</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>
<sup>d</sup>
</td>
<td>
<sup>d</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>
<sup>d</sup>
</td>
<td>
<sup>d</sup>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn34-0748233712436640">
<p>MN: micronucleus; MNBN: micronucleated binuclear cell; SE: standard error; SC: solvent control; PC: positive control; MMC: mitomycin C.</p>
</fn>
<fn id="table-fn35-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn36-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn37-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of MMC.</p>
</fn>
<fn id="table-fn39-0748233712436640">
<p>
<sup>d</sup>Insufficient binuclear cells.</p>
</fn>
<fn id="table-fn40-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p </italic>&lt; 0.05.</p>
</fn>
<fn id="table-fn41-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p </italic>&lt; 0.01.</p>
</fn>
<fn id="table-fn42-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0748233712436640" position="float">
<label>Table 6.</label>
<caption>
<p>The percentage of MN and MNBN in cultured human lymphocytes treated with 4-thujanol + CP in the presence of S9 mix.</p>
</caption>
<graphic alternate-form-of="table6-0748233712436640" xlink:href="10.1177_0748233712436640-table6.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">MNBN ± SE (%)</th>
<th rowspan="2">MN ± SE (%)</th>
<th rowspan="2">Reduction (%)</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>0.23 ± 0.12</td>
<td>0.23 ± 0.12</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>3</td>
<td>4 μL</td>
<td>0.08 ± 0.02</td>
<td>0.08 ± 0.02</td>
<td>
</td>
</tr>
<tr>
<td>PC (CP)</td>
<td>3</td>
<td>28</td>
<td>0.37 ± 0.12</td>
<td>0.37 ± 0.12</td>
<td>
</td>
</tr>
<tr>
<td>4-Thujanol + CP</td>
<td>3</td>
<td>13 + 28</td>
<td>0.22 ± 0.10</td>
<td>0.22 ± 0.10</td>
<td>51.72</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 28</td>
<td>0.38 ± 0.03</td>
<td>0.38 ± 0.03</td>
<td>−3.44</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 28</td>
<td>0.29 ± 0.11</td>
<td>0.29 ± 0.11</td>
<td>27.58</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn43-0748233712436640">
<p>MN: micronucleus; MNBN: micronucleated binuclear cell; SE: standard error; SC: solvent control; PC: positive control; CP: cyclophosphamide.</p>
</fn>
<fn id="table-fn44-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn45-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn46-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of CP.</p>
</fn>
<fn id="table-fn48-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p</italic> &lt; 0.05.</p>
</fn>
<fn id="table-fn49-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p</italic> &lt; 0.01.</p>
</fn>
<fn id="table-fn50-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The observed values of MI, PI, and NDI parameters for all the treatments of 4-thujanol + positive control in the absence and presence of S9 mix are presented in <xref ref-type="table" rid="table7-0748233712436640">Tables 7</xref> and <xref ref-type="table" rid="table8-0748233712436640">8</xref>, respectively. MI decreased significantly (<italic>p</italic> &lt; 0.001) at all concentrations (13 + 0.25, 26 + 0.25, and 52 + 0.25 µg/mL) of 4-thujanol + MMC for the 24- and 48-h treatment periods compared with both the control and solvent control. 4-Thujanol + MMC decreased the MI to the same extent as the independent exposure of MMC for all the concentrations and treatment periods in the absence of S9 mix. At all the tested concentrations, 4-thujanol + MMC caused a statistically significant reduction in the PI when compared with the control and solvent control for the 24-h (<italic>p</italic> &lt; 0.01) and 48-h (<italic>p</italic> &lt; 0.001) treatment periods. Furthermore, the mixture of 4-thujanol + MMC significantly (<italic>p</italic> &lt; 0.05) decreased the PI at the studied concentrations for the 24-h treatment period when compared with the MMC alone. The NDI did not significantly decrease in comparison with the control groups for the 24-h treatment period. The 48-h treatment with 4-thujanol + MMC induced significant decreases in the NDI at all the concentrations when compared with the solvent control. Futhermore, according to the relative values of the MI, PI, and NDI, 4-thujanol + MMC caused a decrease in the MI, PI, and NDI relative to the MMC treatment alone.</p>
<table-wrap id="table7-0748233712436640" position="float">
<label>Table 7.</label>
<caption>
<p>MI, PI, and NDI values in cultured human lymphocytes treated with 4-thujanol + MMC for 24- and 48-h treatment periods.</p>
</caption>
<graphic alternate-form-of="table7-0748233712436640" xlink:href="10.1177_0748233712436640-table7.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">MI ± SE</th>
<th rowspan="2">Relative MI</th>
<th rowspan="2">PI ± SE</th>
<th rowspan="2">Relative PI</th>
<th rowspan="2">NDI ± SE</th>
<th rowspan="2">Relative NDI</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>3.91 ± 0.11</td>
<td>
</td>
<td>1.90 ± 0.06</td>
<td>
</td>
<td>1.223 ± 0.05</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>24</td>
<td>4 μL</td>
<td>3.70 ± 0.23</td>
<td>
</td>
<td>1.88 ± 0.15</td>
<td>
</td>
<td>1.369 ± 0.05</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>24</td>
<td>0.25</td>
<td>1.32 ± 0.05<sup>a3b3</sup>
</td>
<td>100</td>
<td>1.67 ± 0.03</td>
<td>100</td>
<td>1.220 ± 0.07</td>
<td>100</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>24</td>
<td>13 + 0.25</td>
<td>1.13 ± 0.46<sup>a3b3</sup>
</td>
<td>85.6</td>
<td>1.32 ± 0.02<sup>a2b2c1</sup>
</td>
<td>79.0</td>
<td>1.170 ± 0.07</td>
<td>95.9</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>1.10 ± 0.33<sup>a3b3</sup>
</td>
<td>83.3</td>
<td>1.35 ± 0.11<sup>a2b2c1</sup>
</td>
<td>80.8</td>
<td>1.166 ± 0.08</td>
<td>95.5</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>1.12 ± 0.15<sup>a3b3</sup>
</td>
<td>84.8</td>
<td>1.23 ± 0.06<sup>a2b2c1</sup>
</td>
<td>73.6</td>
<td>1.150 ± 0.09</td>
<td>94.2</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>48</td>
<td>4 μL</td>
<td>3.90 ± 0.33</td>
<td>
</td>
<td>2.10 ± 0.02</td>
<td>
</td>
<td>1.402 ± 0.15</td>
<td>
</td>
</tr>
<tr>
<td>PC (MMC)</td>
<td>48</td>
<td>0.25</td>
<td>0.88 ± 0.18<sup>a3b3</sup>
</td>
<td>100</td>
<td>1.05 ± 0.01<sup>a3b3</sup>
</td>
<td>100</td>
<td>1.038 ± 0.02<sup>b2</sup>
</td>
<td>100</td>
</tr>
<tr>
<td>4-Thujanol + MMC</td>
<td>48</td>
<td>13 + 0.25</td>
<td>0.87 ± 0.20<sup>a3b3</sup>
</td>
<td>98.8</td>
<td>1.02 ± 0.01<sup>a3b3</sup>
</td>
<td>97.1</td>
<td>1.007 ± 0.00<sup>b2</sup>
</td>
<td>97.0</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 0.25</td>
<td>0.53 ± 0.10<sup>a3b3d</sup>
</td>
<td>60.2</td>
<td>1.00 ± 0.00<sup>a3b3</sup>
</td>
<td>95.2</td>
<td>1.019 ± 0.00<sup>b2</sup>
</td>
<td>98.1</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 0.25</td>
<td>0.55 ± 0.15<sup>a3b3d</sup>
</td>
<td>62.5</td>
<td>1.005 ± 0.00<sup>a3b3</sup>
</td>
<td>96.7</td>
<td>1.001 ± 0.00<sup>b2</sup>
</td>
<td>96.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn51-0748233712436640">
<p>MI: mitotic index; PI: proliferation index; NDI: nuclear division index; SE: standard error; SC: solvent control; PC: positive control; MMC: mitomycin C.</p>
</fn>
<fn id="table-fn52-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn53-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn54-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of MMC.</p>
</fn>
<fn id="table-fn56-0748233712436640">
<p>
<sup>d</sup>Due to excessive toxicity, a total of 4000 cells were scored per concentration for the mitotic index.</p>
</fn>
<fn id="table-fn57-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p</italic> &lt; 0.05.</p>
</fn>
<fn id="table-fn58-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p</italic> &lt; 0.01.</p>
</fn>
<fn id="table-fn59-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table8-0748233712436640" position="float">
<label>Table 8.</label>
<caption>
<p>MI, PI, and NDI values in cultured human lymphocytes treated with 4-thujanol + CP in the presence of S9 mix.</p>
</caption>
<graphic alternate-form-of="table8-0748233712436640" xlink:href="10.1177_0748233712436640-table8.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Test substance</th>
<th colspan="2">Treatment</th>
<th rowspan="2">MI ± SE</th>
<th rowspan="2">Relative MI</th>
<th rowspan="2">PI ± SE</th>
<th rowspan="2">Relative PI</th>
<th rowspan="2">NDI ± SE</th>
<th rowspan="2">Relative NDI</th>
</tr>
<tr>
<th>Time (h)</th>
<th>Concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−</td>
<td>−</td>
<td>2.98 ± 0.55</td>
<td>
</td>
<td>1.48 ± 0.06</td>
<td>
</td>
<td>1.548 ± 0.14</td>
<td>
</td>
</tr>
<tr>
<td>SC (ethanol, 50%)</td>
<td>3</td>
<td>4 μL</td>
<td>3.01 ± 0.34</td>
<td>
</td>
<td>1.61 ± 0.05</td>
<td>
</td>
<td>1.509 ± 0.10</td>
<td>
</td>
</tr>
<tr>
<td>PC (CP)</td>
<td>3</td>
<td>28</td>
<td>2.53 ± 0.50</td>
<td>100</td>
<td>1.57 ± 0.10</td>
<td>100</td>
<td>1.290 ± 0.28</td>
<td>100</td>
</tr>
<tr>
<td>4-Thujanol + CP</td>
<td>3</td>
<td>13 + 28</td>
<td>2.43 ± 0.53</td>
<td>90.0</td>
<td>1.49 ± 0.09</td>
<td>94.9</td>
<td>1.178 ± 0.16</td>
<td>91.3</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>26 + 28</td>
<td>2.81 ± 0.81</td>
<td>111.0</td>
<td>1.57 ± 0.07</td>
<td>100</td>
<td>1.242 ± 0.16</td>
<td>96.2</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>52 + 28</td>
<td>2.42 ± 0.65</td>
<td>95.6</td>
<td>1.59 ± 0.10</td>
<td>101.2</td>
<td>1.224 ± 0.20</td>
<td>94.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn60-0748233712436640">
<p>MI: mitotic index; PI: proliferation index; NDI: nuclear division index; SE: standard error; SC: solvent control; PC: positive control; CP: cyclophosphamide.</p>
</fn>
<fn id="table-fn61-0748233712436640">
<p>
<sup>a</sup>Significant from control.</p>
</fn>
<fn id="table-fn62-0748233712436640">
<p>
<sup>b</sup>Significant from solvent control.</p>
</fn>
<fn id="table-fn63-0748233712436640">
<p>
<sup>c</sup>Significant from independent exposure of CP.</p>
</fn>
<fn id="table-fn65-0748233712436640">
<p>
<sup>a1b1c1</sup>
<italic>p</italic> &lt; 0.05.</p>
</fn>
<fn id="table-fn66-0748233712436640">
<p>
<sup>a2b2c2</sup>
<italic>p</italic> &lt; 0.01.</p>
</fn>
<fn id="table-fn67-0748233712436640">
<p>
<sup>a3b3c3</sup>
<italic>p</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the presence of S9 mix, cotreatment of 4-thujanol and CP did not make a statistically significant change in the MI, PI, and NDI parameters when compared with the control, solvent control, and independent exposure of CP in PBLs.</p>
<p>In the present study, regression analysis was performed to determine the concentration–response relationship for all the parameters (CA, SCE, MN, MI, PI, and NDI). However, there were no concentration-dependent effects of 4-thujanol + MMC or 4-thujanol + CP on any of these parameters (<italic>p</italic> &gt; 0.05).</p>
</sec>
<sec id="section15-0748233712436640">
<title>Discussion</title>
<p>Our study showed that in the absence of S9 mix, only the lowest concentration of 4-thujanol + MMC (13 + 0.25 µg/mL) weakly reduced the DNA damage induced by MMC for 24-h treatment period by 4.7, 12.3, and 29.5 in CA, SCE, and MN tests, respectively. However, since these reductions were not significant for all the tests, it can be said that 4-thujanol was not able to reduce the damage induced by MMC. Furthermore, the other higher concentrations of the mixtures of 4-thujanol + MMC did not significantly contribute to any reduction in DNA damage. On the other hand, in the presence of S9 mix, all the concentrations of 4-thujanol reduced the genetic damage induced by CP, especially the lowest concentration of 4-thujanol + CP strongly decreased (<italic>p</italic> &lt; 0.001) the frequency of CA, SCE, and MN (49, 55, and 52%, respectively) when compared with the culture treated with CP in a non-concentration-dependent manner.</p>
<p>Our previous study with 4-thujanol has shown that 4-thujanol induced the genetic damage at 13, 26, and 52 µg/mL concentrations in the presence and absence of S9 mix without a concentration-dependent manner using CA, SCE, and MN tests in human PBLs (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>).</p>
<p>Together with our previous investigations, these results show that 4-thujanol has antagonistic potential only against CP-induced genetic damage. Because, the results obtained in this study indicated that the cotreatment of 4-thujanol and CP significantly reduced the frequency of structural CAs, SCEs, and MN formation when compared with the individual exposure of CP in human PBLs.</p>
<p>No data are available on the protective or antagonistic effects of 4-thujanol in the literature. This is the first report on detecting the protective effects of 4-thujanol against genotoxicity induced by mutagenic agents MMC and CP in <italic>in vitro</italic> assay. However, few studies have been carried out on the potential protective effects of some monoterpenoid compounds in various test systems. <xref ref-type="bibr" rid="bibr28-0748233712436640">Horváthová et al. (2009</xref>) reported that higher concentrations of borneol (a bicyclic monoterpene alcohol; 2-h treatment with &gt;2 mM borneol &gt;0.3084 mg/mL) induced cytotoxicity and genotoxicity in primary hepatocyte cultures <italic>in vitro</italic>, but the 7-day supplementation of rats by relatively low concentrations of borneol (in a daily concentration of 17.14 or 34.28 mg/kg) reduced the genotoxicity of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in both hepatocytes and testicular cells. The same research group also reported that thymol (a phenolic monoterpene) and carvacrol (a phenolic monoterpene) reduced the level of DNA damage induced by H<sub>2</sub>O<sub>2</sub> in hepatoma HepG2 cells, colonic caco-2 cells and in human leukemic K562 cells using Comet assay (<xref ref-type="bibr" rid="bibr29-0748233712436640">Horváthová et al., 2006</xref>, <xref ref-type="bibr" rid="bibr30-0748233712436640">2007</xref>). <xref ref-type="bibr" rid="bibr43-0748233712436640">Mitić-Ćulafić et al. (2009</xref>) reported that monoterpenes linalool, myrcene, and eucalyptol efficiently protected bacterial and human cells (HepG2 and B lymphoid NC–NC cells) against genotoxicity of the reactive oxygen species (ROS)-inducing agent (<italic>t</italic>-butyl hydroperoxide, <italic>t</italic>-BOOH) using Ames and Comet assay. <xref ref-type="bibr" rid="bibr65-0748233712436640">Vuković-Gačić et al. (2006</xref>) reported that camphor (a bicyclic monoterpene ketone) showed antimutagenic effect in very low concentration, but higher concentrations of camphor and 1,8-cineole (an etheric monoterpene) did not increase the antimutagenic effect in SY252 using Ames test.</p>
<p>The difference between our results and the literature data could be attributed to the use of different cell lines, different mutagen for the induction of DNA damage, different monoterpene in chemical structure, and different test concentrations.</p>
<p>The mechanism of the decrease in genotoxicity depends on the type of mutagen. Therefore, it is reasonable that the effects of thujanol were found to be different against the genetic damage induced by MMC and CP, in this study.</p>
<p>The results of the present study showed that the tested concentration of 4-thujanol was unable to reduce the genotoxicity of MMC for 24- and 48-h treatment periods in the absence of S9 mix. Therefore, in this test conditions, without S9 metabolic activator, all the tested concentrations of 4-thujanol showed genotoxic activities (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>) and also failed to reduce the damage of MMC. These results are in agreement with <xref ref-type="bibr" rid="bibr5-0748233712436640">Aydın et al. (2005a</xref>) who reported that the concentrations above 0.1 mM (equivalent 14 µg/mL) of gamma terpinene (a monocyclic monoterpene hydrocarbon) significantly induced DNA damage in human lymphocytes; and at all concentrations tested, gamma-terpinene did not show protective effects against H<sub>2</sub>O<sub>2</sub>-induced oxidative DNA damage in human lymphocytes in the Comet assay. <xref ref-type="bibr" rid="bibr6-0748233712436640">Aydın et al. (2005b</xref>) also reported that at concentrations lower than 0.1 mM (equivalent 15 µg/mL) thymol, 0.1 mM (equivalent 14 µg/mL) gamma-terpinene, and 0.05 mM (equivalent 7.5 µg/mL) carvacrol the DNA damage induced by IQ (2-amino-3-methylimidazo[4,5-f]-quinoline) and MMC in human lymphocytes using the single-cell gel electrophoresis was significantly reduced. In our study, 4-thujanol did not show protective effects against MMC-induced genetic damage. But the concentrations used in the present study were 13, 26, and 52 µg/mL, which are relatively high in comparison with the concentrations used in the study of <xref ref-type="bibr" rid="bibr6-0748233712436640">Aydın et al. (2005b</xref>). If we look from this aspect, our results are not contradictory to the results obtained from this study.</p>
<p>MMC is an alkylating agent but does not require exogenous metabolic activator for its mutagenic effects. Hence, 4-thujanol, at the tested concentrations, may not interact with the MMC and inactivate them by chemical reaction. It is also possible that these concentrations of this compound could not alter the binding of the MMC to nucleophilic sites in DNA. 4-Thujanol also may act as a pro-oxidant by affecting the cellular redox status. In eukaryotic cells, essential oils can act as a pro-oxidant affecting the cellular and organelle membranes (especially damage mitochondrial membranes) and provoke depolarization of mitochondrial membranes by decreasing the membrane potential, affecting ionic Ca<sup>2+</sup> cycling (<xref ref-type="bibr" rid="bibr54-0748233712436640">Richter and Schlegel, 1993</xref>; <xref ref-type="bibr" rid="bibr64-0748233712436640">Vercesi et al., 1997</xref>), and changing the fluidity of membranes, resulting in leakage of radicals, cytochrom C, calcium ions, and proteins and leading to cell death by apoptosis and necrosis (<xref ref-type="bibr" rid="bibr4-0748233712436640">Armstrong, 2006</xref>; <xref ref-type="bibr" rid="bibr68-0748233712436640">Yoon et al., 2000</xref>). Thus, when the concentration of antioxidant is not enough to permeabilize to mitochondrial membranes, conversion into pro-oxidant may not occur and the antioxidant would act its activity (<xref ref-type="bibr" rid="bibr8-0748233712436640">Bakkali et al., 2008</xref>). According to this information, we can say that the concentrations of 4-thujanol used in this study (especially 26 and 52 µg/mL) were relatively higher and therefore, 4-thujanol was not able to act as an antioxidant for scavenging radicals induced by MMC.</p>
<p>On the other hand, in our experiments, decreasing the CAs, SCEs, and MN formation due to 4-thujanol against genetic damage caused by CP was observed especially in the presence of the exogenous metabolic activation system, the S9 mix. Thus, it can be said that particularly the metabolites of 4-thujanol may be responsible for the anticlastogenic/antagonistic and DNA protective potential of this compound against CP-induced DNA damage.</p>
<p>CP is also one of the alkylating chemotherapeutic agents that is widely used as an antineoplastic drug in the treatment of wide-spectrum malignancies including leukemia, lymphoma, as well as breast, lung, prostate, and ovarian cancers (<xref ref-type="bibr" rid="bibr33-0748233712436640">Khan et al., 2004</xref>; <xref ref-type="bibr" rid="bibr44-0748233712436640">Moore, 1991</xref>). CP exerts its effects through metabolites; phosphoramide mustard forms DNA cross-links by the formation of covalent bonds between the two alkyl groups and the DNA bases. DNA cross-links lead to DNA strand breaks and then to chromosomal breaks (<xref ref-type="bibr" rid="bibr19-0748233712436640">Crook et al., 1986</xref>; <xref ref-type="bibr" rid="bibr69-0748233712436640">Zhang et al., 2006</xref>). The other active metabolite, acrolein produces high ROS and free radicals that induce oxidative stress (<xref ref-type="bibr" rid="bibr47-0748233712436640">Mythili et al., 2004</xref>). The oxidative damage to genomic DNA by ROS results in the production of covalently modified bases known as DNA adducts, single- and double-strand breaks and in the formation of apurinic/apyrimidinic lesions, which are mutagenically potent contributors to the etiology of genetic diseases (<xref ref-type="bibr" rid="bibr22-0748233712436640">Dizdaroglu, 1992</xref>; <xref ref-type="bibr" rid="bibr41-0748233712436640">Marnett and Burcham, 1993</xref>).</p>
<p>Many monoterpenes (e.g. linalool, myrcene, and eucalyptol) have been found to have antioxidant properties (<xref ref-type="bibr" rid="bibr16-0748233712436640">Celik and Ozkaya, 2002</xref>; <xref ref-type="bibr" rid="bibr55-0748233712436640">Ruberto and Baratta, 2000</xref>; <xref ref-type="bibr" rid="bibr66-0748233712436640">Wang et al., 2008</xref>). <xref ref-type="bibr" rid="bibr43-0748233712436640">Mitić-Ćulafić et al. (2009</xref>) confirmed that the monoterpenoid compounds, linalool and myrcene, had strong radical scavenging activity in Fe<sup>+2</sup>-/ascorbate-induced lipid peroxidation assay <italic>in vitro</italic>. <xref ref-type="bibr" rid="bibr9-0748233712436640">Berić et al. (2008</xref>) reported that linalool reduced spontaneous mutagenesis in mismatch repair-deficient <italic>Escherichia coli</italic> K12 strains, which is indicating that monoterpenes may exert their antimutagenic effects by modulating the DNA repair processes in addition to antioxidant activity.</p>
<p>We suppose that the chemoprotective effect of 4-thujanol can be due to both the antioxidant and antagonistic properties of its metabolites. The antioxidant and antagonistic activity of this compound might be due to scavenging of free radicals and its affinity to the substrates/receptors, respectively. The metabolites of 4-thujanol may donate their electrons to the reactive metabolites of the CP and render them inactive or may bind to specific receptor on the cellular nuclear membrane and thereby prevent binding of CP/metabolites to its receptor. Also probably the metabolites of 4-thujanol may bind to DNA and prevent the ROS and/or mutagenic products to interact directly with the DNA. In addition, the reduction of the genotoxic damage induced by CP could be due to the possible prevention of metabolic activation of CP by 4-thujanol.</p>
<p>For the determination of cytotoxicity/cytostaticity, the MI, PI, and NDI ratios were also evaluated. In our previos study, we found that the same concentrations, as used in this study, of 4-thujanol (13, 26, and 52 µg/mL) did not significantly decrease the MI, PI, and NDI in the presence and absence of S9 mix, which indicate 4-thujanol was neither cytotoxic nor cytostatic agent in human PBLs (<xref ref-type="bibr" rid="bibr35-0748233712436640">Kocaman et al., 2011</xref>). The results of this study revealed that in general, cotreatment of 4-thujanol + MMC to human PBL caused a decrease in the MI, PI, and NDI at all concentrations and treatment times when compared with the control and solvent control, in the absence of S9 mix. These reductions were found to the same extent or more than that of the independent exposure of MMC. On the other hand, in the presence of S9 mix, cotreatment of 4-thujanol and CP did not make a statistically significant change in the MI, PI, and NDI parameters when compared with the control, solvent control, and CP alone in PBLs. Thus, 4-thujanol can be used with such drugs in chemotherapy without reducing their antiproliferative activities.</p>
<p>The present study showed that MMC- and/or CP-induced damage is associated with an increase in choromosomal aberrations in human PBLs. However, 4-thujanol could not reduce the chromosome damage induced by MMC, in this test conditions. On the other hand, probably the metabolites of 4-thujanol act as an antagonist and markedly antagonize CP-induced genotoxicity. Hence, in our study, this monoterpenoid compound significantly reduced the genetic damage induced by CP when compared with the culture treated with CP alone.</p>
<p>In conclusion, 4-thujanol plays a role in reducing chromosomal damage induced by antineoplastic drug, CP. Therefore, it has an antagonistic effect against DNA damage induced by this mutagenic agent. Thus, we can state that 4-thujanol may improve the chemopreventive effects and may also reduce the harmful side effects of CP, which is widely used in chemotherapy against cancer. However, further investigations are needed to better determine the medicinal properties of 4-thujanol in <italic>in vivo</italic> and <italic>in vitro</italic> test systems.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0748233712436640">
<label>Funding</label>
<p>This investigation was supported by a grant from The Scientific and Technical Research Council of Turkey, Ankara (TUBITAK, Project No. 109T546).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albertini</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>) <article-title>IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans</article-title>. <source>Mutation Research</source> <volume>463</volume>: <fpage>111</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr2-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Kalaldeh</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Abu-Dahab</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Afifi</surname>
<given-names>FU</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Volatile oil composition and antiproliferative activity of <italic>Laurus nobilis</italic>, <italic>Origanum syriacum</italic>, <italic>Origanum vulgare</italic>, and <italic>Salvia triloba</italic> against human breast adenocarcinoma cells</article-title>. <source>Nutrition Research</source> <volume>30</volume>: <fpage>271</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr3-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ananthi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Santhiya</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Genotoxic and antigenotoxic effects of <italic>Hemidesmus indicus</italic> R. Br. root extract in cultured lymphocytes</article-title>. <source>Journal of Ethnopharmacology</source> <volume>127</volume>: <fpage>558</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr4-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>JS</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Mitochondrial membrane permeabilization: the sine qua non for cell death</article-title>. <source>BioEssays</source> <volume>28</volume>: <fpage>253</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr5-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aydın</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Başaran</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Başaran</surname>
<given-names>N</given-names>
</name>
</person-group> (<year>2005a</year>). <article-title>Modulating effects of thyme and its major ingredients on oxidative DNA damage in human lymphocytes</article-title>. <source>Journal of Agricultural and Food Chemistry</source> <volume>53</volume>: <fpage>1299</fpage>–<lpage>1305</lpage>.</citation>
</ref>
<ref id="bibr6-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aydın</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Başaran</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Başaran</surname>
<given-names>N</given-names>
</name>
</person-group> (<year>2005b</year>). <article-title>The effects of thyme volatiles on the induction of DNA damage by the heterocyclic amine IQ and mitomycin C</article-title>. <source>Mutation Research</source> <volume>581</volume>: <fpage>43</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr7-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azirak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rencuzogullari</surname>
<given-names>E</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>The in vivo genotoxic effects of carvacrol and thymol in rat bone marrow cells</article-title>. <source>Environmental Toxicology</source> <volume>23</volume>: <fpage>728</fpage>–<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr8-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakkali</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Averbeck</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Averbeck</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Idaomar</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>Biological effects of essential oils-a review</article-title>. <source>Food and Chemical Toxicology</source> <volume>46</volume>: <fpage>446</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr9-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berić</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nikolić</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stanojević</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vuković-Gačić</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Knežević-Vukčević</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>Protective effect of basil (<italic>Ocimum basilicum L</italic>.) against oxidative DNA damage and mutagenesis</article-title>. <source>Food and Chemical Toxicology</source> <volume>46</volume>: <fpage>724</fpage>–<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr10-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatia</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Letizia</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Api</surname>
<given-names>AM</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>Fragrance material review on 4-thujanol</article-title>. <source>Food and Chemical Toxicology</source> <volume>46</volume>: <fpage>295</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr11-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonassi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fenech</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lando</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>) <article-title>Human micronucleus project: international database comparison for results with the cytokinesis block micronucleus assay in human lymphocytes: effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei</article-title>. <source>Environmental and Molecular Mutagenesis</source> <volume>37</volume>: <fpage>31</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr12-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonassi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ugolini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kirsch-Volders</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Strömberg</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Vermeulen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>JD</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Human population with cytogenetic biomarkers: review of the literature and future prospectives</article-title>. <source>Environmental and Molecular Mutagenesis</source> <volume>45</volume>: <fpage>258</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr13-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buyukleyla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rencuzogullari</surname>
<given-names>E</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>The effects of thymol on sister chromatid exchange, chromosome aberration and micronucleus in human lymphocytes</article-title>. <source>Ecotoxicology and Environmental Safety</source> <volume>72</volume>: <fpage>943</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr14-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Candan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Unlu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tepe</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Antioxidant and antimicrobial activity of essential oil and methanol extracts of <italic>Achillea millefolium</italic> subsp<italic>. Millefolium Afan</italic>. (Asteraceae)</article-title>. <source>Journal of Ethnopharmacology</source> <volume>87</volume>: <fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr15-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrano</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>AT</given-names>
</name>
</person-group> (<year>1988</year>) <article-title>Consideration for population monitoring using cytogenetic techniques</article-title>. <source>Mutation Research</source> <volume>204</volume>: <fpage>379</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr16-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ozkaya</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2002</year>) <article-title>Effects of intraperitoneally administered lipoic acid, vitamin E, and linalool on the level of total lipid and fatty acids in guinea pig brain with oxidative stres induced by H<sub>2</sub>O<sub>2</sub>
</article-title>. <source>Journal of Biochemistry and Molecular Biology</source> <volume>35</volume>: <fpage>547</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr17-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celikler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vatan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bilaloglu</surname>
<given-names>R</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>Evaluation of anti-oxidative, genotoxic and antigenotoxic potency of Codium tomentosum Stackhouse ethanolic extract in human lymphocytes in vitro</article-title>. <source>Food and Chemical Toxicology</source> <volume>47</volume>: <fpage>796</fpage>–<lpage>801</lpage>.</citation>
</ref>
<ref id="bibr18-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celikler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vatan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bilaloglu</surname>
<given-names>R</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>In vitro antigenotoxicity of <italic>Ulva rigida </italic>C. Agardh (Chlorophyceae) extract against induction of chromosome aberration, sister chromatid exchange and micronuclei by mutagenic agent MMC</article-title>. <source>Biomedical and Environmental Sciences</source> <volume>21</volume>: <fpage>492</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr19-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crook</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Souhami</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>AE</given-names>
</name>
</person-group> (<year>1986</year>) <article-title>Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells</article-title>. <source>Cancer Research</source> <volume>46</volume>(<issue>10</issue>): <fpage>5029</fpage>–<lpage>5034</lpage>.</citation>
</ref>
<ref id="bibr20-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crowell</surname>
<given-names>PL</given-names>
</name>
</person-group> (<year>1999</year>) <article-title>Prevention and therapy of cancer by dietary monoterpenes</article-title>. <source>Journal of Nutrition</source> <volume>129</volume>: <fpage>775</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr21-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Sotto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mazzanti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hrelia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maffei</surname>
<given-names>F</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Inhibition by β-caryophyllene of ethyl methanesulfonate-induced clatogenicity in cultured human lymphocytes</article-title>. <source>Mutation Research</source> <volume>699</volume>: <fpage>23</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr22-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dizdaroglu</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>1992</year>) <article-title>Oxidative damage to DNA in mammalian chromatin</article-title>. <source>Mutation Research</source> <volume>275</volume>: <fpage>331</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr23-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eastmond</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>JD</given-names>
</name>
</person-group> (<year>1989</year>) <article-title>Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and an anti-kinetochore antibody</article-title>. <source>Environmental and Molecular Mutagenesis</source> <volume>13</volume>: <fpage>34</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr24-0748233712436640">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>HJ</given-names>
</name>
</person-group> (<year>1984</year>) <article-title>Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Kilbey</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Legator</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>Ramel</surname>
<given-names>C</given-names>
</name>
</person-group> (eds) <source>Handbook of Mutagenicity Test Procedures</source>. <edition>2nd ed</edition>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science Publishers</publisher-name>, pp <fpage>405</fpage>–<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr25-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fenech</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>The in vitro micronucleus technique</article-title>. <source>Mutation Research</source> <volume>455</volume>: <fpage>81</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr26-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes-Carneiro</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Felzenszwalb</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Paumgartten</surname>
<given-names>FJR</given-names>
</name>
</person-group> (<year>1998</year>) <article-title>Mutagenicity testing of (±)-camphor, 1,8 cineole, citral, citronellal, (−)-menthol and terpineol with the <italic>Salmonella</italic>/microsome assay</article-title>. <source>Mutation Research</source> <volume>416</volume>: <fpage>129</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr27-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gould</surname>
<given-names>MN</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>Cancer chemoprevention and therapy by monoterpenes</article-title>. <source>Environmental Health Perspectives</source> <volume>105</volume>(<issue>suppl 4</issue>):<fpage>977</fpage>–<lpage>979</lpage>.</citation>
</ref>
<ref id="bibr28-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horváthová</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Slameňova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Maršálková</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Šramková</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wsólová</surname>
<given-names>L</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>Effects of borneol on the level of DNA damage induced in primary rat hepatocytes and testicular cells by hydrogen peroxide</article-title>. <source>Food and Chemical Toxicology</source> <volume>47</volume>: <fpage>1318</fpage>–<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr29-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horváthová</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sramkova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Labaj</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Slamenova</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Study of cytotoxic, genotoxic and DNA-protective effects of selected plant essential oils on human cells cultured in vitro</article-title>. <source>Neuroendocrinology Letters</source> <volume>2</volume>: <fpage>44</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr30-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horváthová</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Turcaňiová</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Slameňova</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>2007</year>) <article-title>Comparative study of DNA-damaging and DNA-protective effects of selected components of essential plant oils in human leukemic cells K562</article-title>. <source>Neoplasma</source> <volume>54</volume>: <fpage>478</fpage>–<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr31-0748233712436640">
<citation citation-type="book">
<collab collab-type="author">IARC</collab> (<year>1987</year>) <source>Monographs on the Evaluation of Carcinogenic Risks to Human. Overall Evaluation of Carcinogenicity</source>. <volume>Vol. 42</volume>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>International Agency for Research on Cancer</publisher-name>.</citation>
</ref>
<ref id="bibr32-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayraldız</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kocaman</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Rencüzoğulları</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>) <article-title>The genotoxic and antigenotoxic effects of <italic>Aloe vera</italic> leaf extract in vivo and in vitro</article-title>. <source>Turkish Journal of Biology</source> <volume>34</volume>: <fpage>235</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr33-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Sundin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Juhlin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilander</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Oberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>B</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer</article-title>. <source>Medical Oncology</source> <volume>21</volume>: <fpage>167</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr34-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsch-Volders</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sofuni</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aardema</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Report from the in vitro micronucleus assay working group</article-title>. <source>Mutation Research</source> <volume>540</volume>: <fpage>153</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr35-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kocaman</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Rencüzoğulları</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Topaktaş</surname>
<given-names>M</given-names>
</name>
<name>
<surname>İstifli</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Büyükleyla</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>The effects of 4-thujanol on chromosome aberrations, sister chromatid exchanges and micronucleus in human peripheral blood lymphocytes</article-title>. <source>Cytotechnology</source> <volume>63</volume>(<issue>5</issue>): <fpage>493</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr36-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kordalı</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kotan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mavi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Çakır</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ala</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yıldırım</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Determination of the chemical composition and antioxidant activity of the essential oil of <italic>Artemisia dracunculus</italic> and of the antifungal and antibacterial activities of Turkish <italic>Artemisia absinthium</italic>, <italic>Artemisia dracunculus</italic>, <italic>Artemisia santonicum</italic> and <italic>Artemisia spicigera</italic> essential oils</article-title>. <source>Journal of Agricultural and Food Chemistry</source> <volume>53</volume>: <fpage>9452</fpage>–<lpage>9458</lpage>.</citation>
</ref>
<ref id="bibr37-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Köse</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Deniz</surname>
<given-names>İG</given-names>
</name>
<name>
<surname>Sarıkürkçü</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aktaş</surname>
<given-names>Ö</given-names>
</name>
<name>
<surname>Yavuz</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Chemical composition, antimicrobial and antioxidant activities of the essential oils of <italic>Sideritis erythrantha</italic> Boiss. and Heldr. (var. <italic>erythrantha </italic>and var. <italic>cedretorum</italic> P.H. Davis) endemic in Turkey</article-title>. <source>Food and Chemical Toxicology</source> <volume>48</volume>: <fpage>2960</fpage>–<lpage>2965</lpage>.</citation>
</ref>
<ref id="bibr38-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamberti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ponzetto</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Ardito</surname>
<given-names>G</given-names>
</name>
</person-group> (<year>1983</year>) <article-title>Cell kinetics and sister chromatid exchange frequency in human lymphocytes</article-title>. <source>Mutation Research</source> <volume>319</volume>: <fpage>193</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr39-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mace</surname>
<given-names>MLJ</given-names>
</name>
<name>
<surname>Daskal</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wray</surname>
<given-names>W</given-names>
</name>
</person-group> (<year>1978</year>) <article-title>Scanning electron microscopy of chromosome aberrations</article-title>. <source>Mutation Research</source> <volume>52</volume>: <fpage>199</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr40-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manoharan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>MR</given-names>
</name>
</person-group> (<year>1985</year>) <article-title>Beta-carotene reduces sister chromatid exchange induce chemical carcinogens in mouse mammary cell in organ culture</article-title>. <source>Cell Biology International Reports</source> <volume>9</volume>: <fpage>783</fpage>–<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr41-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marnett</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Burcham</surname>
<given-names>P</given-names>
</name>
</person-group> (<year>1993</year>) <article-title>Endogenous DNA adducts: potential and paradox</article-title>. <source>Chemical Research in Toxicology</source> <volume>6</volume>: <fpage>771</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr42-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maron</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ames</surname>
<given-names>BN</given-names>
</name>
</person-group> (<year>1983</year>) <article-title>Revised methods for the Salmonella mutagenicity test</article-title>. <source>Mutation Research</source> <volume>113</volume>: <fpage>173</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr43-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitić-Ćulafić</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Žegura</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nicolić</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vuković-Gačić</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Knežević-Vukčević</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filipič</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>Protective effect of linalool, myrcene and eucalyptol against t-butyl hydroperoxide induced genotoxicity in bacteria and cultured human cells</article-title>. <source>Food and Chemical Toxicology</source> <volume>47</volume>: <fpage>260</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr44-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>MJ</given-names>
</name>
</person-group> (<year>1991</year>) <article-title>Clinical pharmacokinetics of cyclophosphamide</article-title>. <source>Clinical Pharmacokinetics</source> <volume>20</volume>: <fpage>194</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr46-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moteki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hibasami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Katsuzaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Komiya</surname>
<given-names>T</given-names>
</name>
</person-group> (<year>2002</year>) <article-title>Specific induction of apoptosis by 1,8 cineole in two human leukemia cell lines, but not in human stomach cancer line</article-title>. <source>Oncology Reports</source> <volume>9</volume>: <fpage>757</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr47-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mythili</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sudharsan</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Selvakumar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Varalakshmi</surname>
<given-names>P</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Protective effect of DL-alpha-lipoic acid on cyclophosphamide induced oxidative cardiac injury</article-title>. <source>Chemico-Biological Interactions</source> <volume>151</volume>(<issue>1</issue>): <fpage>13</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr48-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Negi</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Jayaprakasha</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Jena</surname>
<given-names>BS</given-names>
</name>
</person-group> (<year>2003</year>) <article-title>Antioxidant and antimutagenic activities of pomegranate peel extracts</article-title>. <source>Food Chemistry</source> <volume>80</volume>: <fpage>393</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr49-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishida</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tamotsu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Allelopathic effects of volatile monoterpenoids produced by <italic>Salvia leucophylla</italic> inhibition of cell proliferation and DNA synthesis in the root apical meristem of <italic>Brassica campestris</italic> seedlings</article-title>. <source>Journal of Chemical Ecology</source> <volume>31</volume>: <fpage>187</fpage>–<lpage>1203</lpage>.</citation>
</ref>
<ref id="bibr50-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pattnaik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Subramanyam</surname>
<given-names>VR</given-names>
</name>
<name>
<surname>Bapaji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Köle</surname>
<given-names>CR</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>Antibacterial and antifungal activity of aromatic constituents of essential oils</article-title>. <source>Microbios</source> <volume>89</volume>: <fpage>39</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr51-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paz-y-Miño</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bustamante</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sánchez</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>PE</given-names>
</name>
</person-group> (<year>2002</year>) <article-title>Cytogenetic monitoring in a population occupationally exposed to pesticides in Ecuador</article-title>. <source>Environmental Health Perspectives</source> <volume>110</volume>: <fpage>1077</fpage>–<lpage>1080</lpage>.</citation>
</ref>
<ref id="bibr52-0748233712436640">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>EJ</given-names>
</name>
</person-group> (<year>1984</year>) <article-title>The methodology of sister chromatid exchanges</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Kilbey</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Legator</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>W,</given-names>
</name>
<name>
<surname>Ramel</surname>
<given-names>C</given-names>
</name>
</person-group> (eds) <source>Handbook of Mutagenicity Test Procedures</source>. <edition>2nd ed</edition>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science Publishers</publisher-name>, pp <fpage>495</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr53-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rencuzogullari</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ila</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Kayraldiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Diler</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Yavuz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arslan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Topaktas</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>The mutagenic and antimutagenic effects of <italic>Ecballium elaterium</italic> fruit juice in human peripheral lymphocytes</article-title>. <source>Russian Journal of Genetics</source> <volume>42</volume>: <fpage>623</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr54-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlegel</surname>
<given-names>J</given-names>
</name>
</person-group>, (<year>1993</year>) <article-title>Mitochondrial calcium release induced by prooxidants</article-title>. <source>Toxicology Letters</source> <volume>67</volume>: <fpage>119</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr55-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruberto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baratta</surname>
<given-names>MT</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Antioxidant activity of selected essential oil components in two lipid model systems</article-title>. <source>Food Chemistry</source> <volume>69</volume>: <fpage>167</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr56-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sangun</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Timur</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karadeniz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Caliskan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozkan</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2007</year>) <article-title>Comparison of chemical composition of the essential oil of <italic>Laurus nobilis</italic> L. leaves and fruits from different regions of Hatay, Turkey</article-title>. <source>Journal of Environmental Biology</source> <volume>28</volume>: <fpage>731</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr57-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>de Araújo</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Lima Júnior</surname>
<given-names>RCP</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>VSN</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>1,8-cineole (eucalyptol), a monoterpene oxide attenuates the colonic damage in rats on acute TNBS-colitis</article-title>. <source>Food and Chemical Toxicology</source> <volume>42</volume>: <fpage>579</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr58-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slamenova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Horvathova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chalupa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wsolova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Navarova</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>Ex vivo assessment of protective effects of carvacrol against DNA lesions induced in primary rat cells by visible light excited methylene blue (VL+MB)</article-title>. <source>Neoplasma</source> <volume>58</volume>(<issue>1</issue>): <fpage>14</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr59-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorsa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hemminki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vainio</surname>
<given-names>H</given-names>
</name>
</person-group> (<year>1985</year>) <article-title>Occupational exposure to anti-cancer drugs: potential and hazard</article-title>. <source>Mutation Research</source> <volume>154</volume>: <fpage>135</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr60-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sowjanya</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Devi</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Madhavi</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Modulatory effects of garlic extract against the cyclophosphamide induced genotoxicity in human lymphocytes in vitro</article-title>. <source>Journal of Environmental Biology</source> <volume>30</volume>: <fpage>663</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr61-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Speit</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Haupter</surname>
<given-names>S</given-names>
</name>
</person-group> (<year>1985</year>) <article-title>On the mechanism of differantial giemsa staining of bromodeoxyuridine-substituted chromosomes. II. differences between the demonstration of sister chromatid differentiation and replication patterns</article-title>. <source>Human Genetics</source> <volume>70</volume>: <fpage>126</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr62-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tepe</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Donmez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Unlu</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Antimicrobial and antioxidative activities of the essential oils and methanol extracts of <italic>Salvia cryptantha</italic> (Montbret et Aucher ex Benth.) and <italic>Salvia multicaulis </italic>(Vahl)</article-title>. <source>Food Chemistry</source> <volume>84</volume>: <fpage>519</fpage>–<lpage>525</lpage>.</citation>
</ref>
<ref id="bibr63-0748233712436640">
<citation citation-type="book">
<collab collab-type="author">VCF</collab> (<year>2010</year>) <article-title>Volatile compounds</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Ingen-Visscher</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Van</surname>
<given-names>CA,</given-names>
</name>
<name>
<surname>Donders</surname>
<given-names>JJH</given-names>
</name>
</person-group>, (eds) <source>Food: Database/Nijssen</source>. <edition>Version 12.2</edition>. <publisher-loc>Zeist (The Netherlands)</publisher-loc>: <publisher-name>TNO Quality of Life 1963-2010</publisher-name>.</citation>
</ref>
<ref id="bibr64-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vercesi</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kowaltowski</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Grijalba</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Meinicke</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Castilho</surname>
<given-names>RF</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>The role of reactive oxygen species in mitochondrial permeability transition</article-title>. <source>Bioscience Reports</source> <volume>17</volume>: <fpage>43</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr65-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vuković-Gačić</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nikčević</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berić-Bjedov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Knežević-Vukčević</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Simić</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Antimutagenic effect of essential oil of sage (<italic>Salvia officinalis</italic> L.) and its monoterpenes against UV-induced mutations in <italic>Escherichia coli</italic> and <italic>Saccharomyces cerevisiae</italic>
</article-title>. <source>Food and Chemical Toxicology</source> <volume>44</volume>: <fpage>1730</fpage>–<lpage>1738</lpage>.</citation>
</ref>
<ref id="bibr66-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zu</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>YJ</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>Antioxidative activity of <italic>Rosmanirus officinalis</italic> L. Essential oil compared to its main components</article-title>. <source>Food Chemistry</source> <volume>108</volume>: <fpage>1019</fpage>–<lpage>1022</lpage>.</citation>
</ref>
<ref id="bibr67-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waters</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Stack</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Brockman</surname>
<given-names>HE</given-names>
</name>
</person-group> (<year>1990</year>) <article-title>Antimutegenic profiles for some model compounds</article-title>. <source>Mutation Research</source> <volume>238</volume>: <fpage>57</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr68-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>YH</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>Genistein induces apoptosis of RPE-J cells by opening mitochondrial PTP</article-title>. <source>Biochemical and Biophysical Research Communications</source> <volume>276</volume>: <fpage>151</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr69-0748233712436640">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Clinical pharmacology of cyclophosphamide and Ifosfamide</article-title>. <source>Current Drug Therapy</source> <volume>1</volume>(<issue>1</issue>): <fpage>55</fpage>–<lpage>84</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>